Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 3Completed 3Active not recruiting 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Biliary Tract Neoplasms 3

Interventions

Oxaliplatin 95Fluorouracil 84Capecitabine 75Gemcitabine 72Leucovorin 68Nivolumab 67Bevacizumab 63pembrolizumab 61Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 39Paclitaxel 37Biopsy 37130-nm albumin-bound paclitaxel 34Cetuximab 30Carboplatin 27Albumin-Bound Paclitaxel 26Taxes 24Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Standard of Care 17Docetaxel 17trifluridine tipiracil drug combination 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × gemcitabine-oxaliplatin regimen × Gastrointestinal × Clear all
NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT03478488 2025-05-29

KN035-BTC

3D Medicines

Phase 3 Active not recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06975917 2025-05-16

TOG-SAFRADJU

Ankara University

Active not recruiting
600 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡